Please use this identifier to cite or link to this item:
Title: A Phase II Study of Risk-Adapted Intravenous Melphalan in patients with AL Amyloidosis
Authors: Mollee, P.;Tiley, Campbell ;Cunningham, I.;Moore, J.;Prince, M.;Cannell, P.;Gibbons, S.;Tate, J.;Paul, S.;Mar Fan, H.;Gill, Devinder S 
Issue Date: Jun-2012
Source: Volume 157, Issue 6, pp. 766-769
Journal title: British Journal of Haematology
Abstract: First Paragraph: Melphalan is a cornerstone of treatment for AL amyloidosis. Intravenous (IV) melphalan is used for patients suitable for autologous stem cell transplantation (ASCT), while oral mel- phalan and dexamethasone is standard treatment for patients unsuited for intensive therapy. IV melphalan, however, may have some advantages in non-ASCT eligible patients with AL amyloidosis, based on unpredictable oral absorption (Bo- sanquet & Gilby, 1984) and theoretical concern that gastroin- testinal involvement may further impair absorption (Sattianayagam et al, 2009).
DOI: 10.1111/j.1365-2141.2012.09080.x
ISSN: 1365-2141
Publicaton type: Journal Article
Keywords: Cancer
Drug Therapy
Study or Trial: Clinical Trial
Appears in Collections:Oncology / Cancer

Show full item record

Page view(s)

checked on Jan 31, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.